Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis.

Autor:	Amonkar MM; Merck & Co., Inc., Rahway, NJ 07065, USA., Abderhalden LA; MSD, 8058, Zurich, Switzerland., Fox GE; PRECISIONheor, New York, NY 11203, USA., Frederickson AM; PRECISIONheor, New York, NY 11203, USA., Grira T; Cytel France, 75002, Paris, France., Gozman A; Merck & Co., Inc., Rahway, NJ 07065, USA., Malhotra U; Merck & Co., Inc., Rahway, NJ 07065, USA., Malbecq W; MSD-Europe, 1170, Brussels, Belgium., Akers KG; PRECISIONheor, New York, NY 11203, USA.
Jazyk:	angličtina
Zdroj:	Future oncology (London, England) [Future Oncol] 2024 Apr; Vol. 20 (13), pp. 863-876. Date of Electronic Publication: 2024 Feb 14.
DOI:	10.2217/fon-2023-0006
Abstrakt:	Aim: A systematic review and meta-analysis were performed to evaluate the efficacy of treatments for previously treated advanced biliary tract cancer (BTC) patients. Materials & methods: Databases were searched for studies evaluating treatments for advanced (unresectable and/or metastatic) BTC patients who progressed on prior therapy. Pooled estimates of objective response rate (ORR), median overall survival (OS) and median progression-free survival (PFS) were calculated using random effects meta-analysis. Results: Across 31 studies evaluating chemotherapy or targeted treatment regimens in an unselected advanced BTC patient population, pooled ORR was 6.9%, median OS was 6.6 months and median PFS was 3.2 months. Conclusion: The efficacy of conventional treatments for previously treated advanced BTC patients is poor and could be improved by novel therapies.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu